89809-64-3

Usage

Uses

Used in Organic Synthesis:
5-Chloro-2-cyanopyridine is used as a key intermediate in the synthesis of various organic compounds. Its presence of both a chloro and a cyano group allows for versatile chemical reactions, such as nucleophilic substitution, addition, and cyclization, making it a valuable building block for the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Chloro-2-cyanopyridine is used as a starting material for the synthesis of various drug candidates. Its unique structure and reactivity enable the creation of novel compounds with potential therapeutic applications, such as antimicrobial, antiviral, and anticancer agents.
Used in Agrochemical Industry:
5-Chloro-2-cyanopyridine is also utilized in the agrochemical industry for the development of new pesticides and herbicides. Its chemical properties allow for the design of innovative molecules with improved efficacy and selectivity, contributing to more effective and environmentally friendly crop protection solutions.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 5-Chloro-2-cyanopyridine is employed as a precursor for the synthesis of various dyes and pigments. Its ability to form stable chromophores and participate in conjugated systems makes it suitable for the production of colorants with high color strength, stability, and fastness properties.
Used in Research and Development:
5-Chloro-2-cyanopyridine is used as a research compound in academic and industrial laboratories. Its unique structure and reactivity make it an interesting subject for studying various chemical reactions and mechanisms, as well as for exploring its potential applications in materials science, catalysis, and other fields.

InChI:InChI=1/C6H3ClN2/c7-5-1-2-6(3-8)9-4-5/h1-2,4H

Upstream product

• 460-19-5 ethanedinitrile 
• 126-99-8 chloroprene 
• 616-47-7 1-methyl-1H-imidazole 
• 67-66-3 chloroform 
• 4513-94-4 1H-pyrrole-2-carbonitrile 
• 1851-22-5 3-chloropyridine-N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 544-92-3 copper(I) cyanide 
• 244221-57-6 5-chloro-2-iodo-pyridine 
• 16110-09-1 2,5 dichloropyridine 
• 40473-01-6 2-Bromo-5-chloro-pyridine 
• 626-60-8 3-Chloropyridine 
• 31181-89-2 5-chloro-2-pyridine carboxaldehyde 
• 10177-25-0 5-chloro-pyridine-2-carbaldehyde oxime 

Downstream Products

• 327056-55-3 5-chloro-N'-hydroxypyridine-2-carboximidamide 
• 943621-63-4 2-(5-chloropyridine-2-yl)-1H-imidazoline 
• 94952-46-2 1-(5-chloropyridin-2-yl)ethan-1-one 
• 871020-42-7 5-(4-amino-2-methylphenoxy)pyridine-2-carbonitrile 
• 67938-76-5 (5-chloropyridin-2-yl)methanamine 
• 188918-74-3 5-cyclopropylpyridine-2-carbonitrile 
• 1086107-46-1 (S)-5-(2-(1-cyclohexylethylamino)benzo[d]thiazol-6-yloxy)picolinonitrile 
• 1211973-83-9 C₁₁H₁₂N₄O₃S 
• 1255650-79-3 6-cyano-N-(piperidine-1-carbonyl)nicotinamide 
• 1257310-80-7 (6-cyanopyridin-3-yl)-carbamic acid 2-trimethylsilanylethyl ester 
• 939039-26-6 1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethanamine 
• 939039-44-8 (5-chloropyridin-2-yl)(3-fluoro-5-(trifluoromethyl)phenyl)methanimine 
• 939039-29-9 (5-chloropyridin-2-yl)(3-fluoro-5-(trifluoromethyl)phenyl)methanone 
• 939420-31-2 1-(5-chloropyridin-2-yl)-2-phenyl-1-(3-(trifluoromethoxy)phenyl)ethanamine 

Relevant academic research and scientific papers

A Transition-Metal-Free One-Pot Cascade Process for Transformation of Primary Alcohols (RCH2OH) to Nitriles (RCN) Mediated by SO2F2

A new transition-metal-free one-pot cascade process for the direct conversion of alcohols to nitriles was developed without introducing an “additional carbon atom”. This protocol allows transformations of readily available, inexpensive, and abundant alcohols to highly valuable nitriles.

C?H Cyanation of 6-Ring N-Containing Heteroaromatics

Heteroaromatic nitriles are important compounds in drug discovery, both for their prevalence in the clinic and due to the diverse range of transformations they can undergo. As such, efficient and reliable methods to access them have the potential for far-reaching impact across synthetic chemistry and the biomedical sciences. Herein, we report an approach to heteroaromatic C?H cyanation through triflic anhydride activation, nucleophilic addition of cyanide, followed by elimination of trifluoromethanesulfinate to regenerate the cyanated heteroaromatic ring. This one-pot protocol is simple to perform, is applicable to a broad range of decorated 6-ring N-containing heterocycles, and has been shown to be suitable for late-stage functionalization of complex drug-like architectures.

HYDRAZONE COMPOUNDS AND THEIR USE

The present invention relates to hydrazone compounds of Formula I: (I) and pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3, R4, L1, and L2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I as inhibitors of TRPM5 protein.

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.

Discovery and structure-activity relationship of 3-aryl-5-aryl-1,2,4- oxadiazoles as a new series of apoptosis inducers and potential anticancer agents

We have identified 5-(3-chlorothiophen-2-yl)-3-(4-trifluoromethylphenyl)-1, 2,4-oxadiazole (1d) as a novel apoptosis inducer through our caspase- and cell-based high-throughput screening assay. Compound 1d has good activity against several breast and colorectal cancer cell lines but is inactive against several other cancer cell lines. In a flow cytometry assay, treatment of T47D cells with 1d resulted in arrest of cells in the G1 phase, followed by induction of apoptosis. SAR studies of Id showed that the 3-phenyl group can be replaced by a pyridyl group, and a substituted five-member ring in the 5-position is important for activity. 5-(3-Chlorothiophen-2-yl)-3-(5- chloropyridin-2-yl)-1,2,4-oxadiazole (41) has been found to have in vivo activity in a MX-1 tumor model. Using a photoaffinity agent, the molecular target has been identified as TIP47, an IGFII receptor binding protein. Therefore, our cell-based chemical genetics approach for the discovery of apoptosis inducers can identify potential anticancer agents as well as their molecular targets.

Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof

The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Triazole derivative and pharmaceutical use thereof

An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) STR1 or the following formula (III) STR2 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

Site-Selectivity in the Cyanation of 3-Substituted Pyridine 1-Oxides with Trimethylsilanecarbonitrile

The cyanation of 3-halo-, 3-methoxy-, and 3-dimethylaminopyridine 1-oxide with trimethylsilanecarbonitrile gave predominantly the corresponding 3-substituted 2-pyridinecarbonitriles.The deoxygenation of nitropyridine 1-oxides to nitropyridines with the same reagent is also described.Keywords - site-selective reaction; trimethylsilanecarbonitrile; pyridine 1-oxide; 2-pyridine-carbonitrile; nitropyridine 1-oxide; deoxygenation; aromatic amine N-oxide; cyanation

REGIOSELECTIVE CYANATION OF 3-SUBSTITUTED PYRIDINE 1-OXIDES

Cyanation of 3-X-pyridine 1-oxides with trimethylsilanecarbonitrile and dimethylcarbamoyl chloride occurs quantitatively to give 3-X-pyridinecarbonitriles in > 90percent isolated yields when X = -CH3, -OCH3, -OH and -Cl, and approximately equal amounts of the 3- and 5-X derivatives when X = -CN and -COOCH3.